FEC (fluorouracil, epirubicin, cyclophosphamide) plus granulocyte macrophage-colony stimulating factor (GM-CSF) in advanced or inflammatory breast cancer. A dose finding study

V. Lorusso, C. Tatulli, F. Berardi, M. Brandi, A. De Mitrio, A. Cataldi, A. Fioretto, R. Sarcina, F. Schittulli, M. De Lena

Research output: Contribution to journalArticle

Abstract

Seven patients with inflammatory and 11 with metastatic breast cancer were treated with high dose FEC chemotherapy plus GM-CSF; 5-fluorouracil and cyclophosphamide were administered at 500 mg/m2/iv/ day 1, epirubicin at three dose levels: 100 mg, 120 mg and 140 mg/m2/iv/day 1 every three weeks (six patients per level). GM-CSF was administered at a dosage of 5 mg/kg/sc from day 5 to 12 of each cycle. The overall response rate was 83% (95% CI: 66%-100%) with 22% complete response. The median response duration for patients with metastatic disease was 7 months (range: 4-10). The hematological toxicity was moderate but reversible due to GM-CSF rescue; mucositis represented the dose limiting toxicity. In conclusion, the increase of dose intensity resulted in a higher response rate but not longer response duration, which must be taken into account when administering high-dose chemotherapy with growth factor rescue.

Original languageEnglish
Pages (from-to)223-228
Number of pages6
JournalInternational Journal of Oncology
Volume3
Issue number2
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'FEC (fluorouracil, epirubicin, cyclophosphamide) plus granulocyte macrophage-colony stimulating factor (GM-CSF) in advanced or inflammatory breast cancer. A dose finding study'. Together they form a unique fingerprint.

  • Cite this

    Lorusso, V., Tatulli, C., Berardi, F., Brandi, M., De Mitrio, A., Cataldi, A., Fioretto, A., Sarcina, R., Schittulli, F., & De Lena, M. (1993). FEC (fluorouracil, epirubicin, cyclophosphamide) plus granulocyte macrophage-colony stimulating factor (GM-CSF) in advanced or inflammatory breast cancer. A dose finding study. International Journal of Oncology, 3(2), 223-228.